ebselen has been researched along with Brain Ischemia in 22 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 9.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 5.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Pretreatment with ebselen prevented the death by 56% and attenuated neurological damage (abnormal eyelid drooping, hair bristling, muscle tone, flexor reflex, posture, and walking patterns)." | 5.40 | Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils. ( Daily, JW; Kang, S; Kim, DS; Moon, NR; Park, S; Shin, BK, 2014) |
| "Ebselen is a mimic of glutathione peroxidase that reacts with peroxynitrite and inhibits nitric oxide (NO) synthase." | 5.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "In ebselen-treated rats, the extent of tissue immunopositive for 8-oxodGuo, and 4-HNE was less than that demonstrating ischemic damage confirming the antioxidant mechanism of action in vivo." | 5.32 | Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. ( Graham, DI; Imai, H; Macrae, IM; Masayasu, H, 2003) |
| "Pretreatment with ebselen, which induced significant (P < 0." | 5.32 | Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. ( Alborch, E; Burguete, MC; Marín, N; Pérez-Asensio, FJ; Pitarch, C; Romero, FJ; Salom, JB; Torregrosa, G, 2004) |
| "Ebselen treatment resulted in a significant lowering of IL-6 plasma levels (26 +/- 5 pg/ml) as compared with that seen in lesioned vehicle controls (48 +/- 9 pg/ml) at 24 h postlesion." | 5.31 | Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. ( Arteel, GE; Bidmon, HJ; Divanach, A; Gladilin, S; Sies, H; Witte, OW; Zilles, K, 2000) |
| "The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action, on the outcome of subarachnoid hemorrhage was evaluated in a multicenter placebo-controlled double-blind clinical trial." | 5.08 | Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. ( Abe, H; Asano, T; Ishibashi, S; Kikuchi, H; Ohta, T; Saito, I; Sano, K; Takakura, K; Yoshimoto, T, 1998) |
| " Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents." | 4.82 | Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005) |
| "LFB staining was used to detect demyelination." | 1.91 | Ebselen alleviates white matter lesions and improves cognitive deficits by attenuating oxidative stress via Keap1/Nrf2 pathway in chronic cerebral hypoperfusion mice. ( Cheng, B; Dong, F; Liu, Y; Meng, Q; Song, X; Yan, W; Yao, R, 2023) |
| "Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue." | 1.40 | Effects of ebselen on ischemia/reperfusion injury in rat brain. ( Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014) |
| "Pretreatment with ebselen prevented the death by 56% and attenuated neurological damage (abnormal eyelid drooping, hair bristling, muscle tone, flexor reflex, posture, and walking patterns)." | 1.40 | Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils. ( Daily, JW; Kang, S; Kim, DS; Moon, NR; Park, S; Shin, BK, 2014) |
| "Ebselen is a mimic of glutathione peroxidase that reacts with peroxynitrite and inhibits nitric oxide (NO) synthase." | 1.37 | Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. ( Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011) |
| "In ebselen-treated rats, the extent of tissue immunopositive for 8-oxodGuo, and 4-HNE was less than that demonstrating ischemic damage confirming the antioxidant mechanism of action in vivo." | 1.32 | Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. ( Graham, DI; Imai, H; Macrae, IM; Masayasu, H, 2003) |
| "Pretreatment with ebselen, which induced significant (P < 0." | 1.32 | Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. ( Alborch, E; Burguete, MC; Marín, N; Pérez-Asensio, FJ; Pitarch, C; Romero, FJ; Salom, JB; Torregrosa, G, 2004) |
| "Ebselen treatment resulted in a significant lowering of IL-6 plasma levels (26 +/- 5 pg/ml) as compared with that seen in lesioned vehicle controls (48 +/- 9 pg/ml) at 24 h postlesion." | 1.31 | Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. ( Arteel, GE; Bidmon, HJ; Divanach, A; Gladilin, S; Sies, H; Witte, OW; Zilles, K, 2000) |
| "Ebselen (EBS) is a seleno-organic compound with glutathione peroxidase-like activity which is neuroprotective in acute stroke ischemia." | 1.31 | Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat. ( Mello, CF; Rocha, JB; Rossato, JI; Rubin, MA; Zeni, G, 2002) |
| "3." | 1.30 | Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. ( Graham, DI; Macrae, IM; Masayasu, H; Peters, EE; Takasago, T, 1997) |
| "Pretreatment with ebselen (10 or 30 mg/kg p." | 1.29 | The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. ( Dawson, DA; Graham, DI; Macrae, IM; Masayasu, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KM | 1 |
| Kim, KH | 1 |
| Kang, TC | 1 |
| Kim, WY | 1 |
| Lee, Mr | 1 |
| Jung, HJ | 1 |
| Hwang, IK | 2 |
| Ko, SB | 1 |
| Koh, JY | 1 |
| Won, MH | 2 |
| Oh, Eg | 1 |
| Shin, I | 1 |
| Dong, F | 1 |
| Yan, W | 1 |
| Meng, Q | 1 |
| Song, X | 1 |
| Cheng, B | 1 |
| Liu, Y | 1 |
| Yao, R | 1 |
| Aras, M | 1 |
| Altaş, M | 1 |
| Meydan, S | 1 |
| Nacar, E | 1 |
| Karcıoğlu, M | 1 |
| Ulutaş, KT | 1 |
| Serarslan, Y | 1 |
| Park, S | 1 |
| Kang, S | 1 |
| Kim, DS | 1 |
| Shin, BK | 1 |
| Moon, NR | 1 |
| Daily, JW | 1 |
| Wong, CH | 1 |
| Bozinovski, S | 1 |
| Hertzog, PJ | 1 |
| Hickey, MJ | 1 |
| Crack, PJ | 1 |
| Seo, JY | 1 |
| Lee, CH | 1 |
| Cho, JH | 1 |
| Choi, JH | 1 |
| Yoo, KY | 1 |
| Kim, DW | 1 |
| Park, OK | 1 |
| Li, H | 1 |
| Choi, SY | 1 |
| Bordet, R | 1 |
| Ouk, T | 1 |
| Onténiente, B | 1 |
| Charriaut-Marlangue, C | 1 |
| Heurteaux, C | 1 |
| Koizumi, H | 1 |
| Fujisawa, H | 1 |
| Suehiro, E | 1 |
| Shirao, S | 1 |
| Suzuki, M | 1 |
| Imai, H | 2 |
| Graham, DI | 4 |
| Masayasu, H | 5 |
| Macrae, IM | 4 |
| Salom, JB | 1 |
| Pérez-Asensio, FJ | 1 |
| Burguete, MC | 1 |
| Marín, N | 1 |
| Pitarch, C | 1 |
| Torregrosa, G | 1 |
| Romero, FJ | 1 |
| Alborch, E | 1 |
| Green, AR | 1 |
| Ashwood, T | 1 |
| Shi, H | 1 |
| Liu, S | 1 |
| Miyake, M | 1 |
| Liu, KJ | 1 |
| Dawson, DA | 1 |
| Takasago, T | 1 |
| Peters, EE | 1 |
| Yamaguchi, T | 1 |
| Sano, K | 2 |
| Takakura, K | 3 |
| Saito, I | 2 |
| Shinohara, Y | 1 |
| Asano, T | 3 |
| Yasuhara, H | 1 |
| Abe, H | 1 |
| Yoshimoto, T | 1 |
| Kikuchi, H | 1 |
| Ohta, T | 1 |
| Ishibashi, S | 1 |
| Bastianetto, S | 1 |
| Zheng, WH | 1 |
| Quirion, R | 1 |
| Gladilin, S | 1 |
| Bidmon, HJ | 1 |
| Divanach, A | 1 |
| Arteel, GE | 1 |
| Witte, OW | 1 |
| Zilles, K | 1 |
| Sies, H | 2 |
| Parnham, M | 1 |
| Dewar, D | 1 |
| Rossato, JI | 1 |
| Zeni, G | 1 |
| Mello, CF | 1 |
| Rubin, MA | 1 |
| Rocha, JB | 1 |
| Johshita, H | 1 |
| Sasaki, T | 1 |
| Matsui, T | 1 |
| Hanamura, T | 1 |
3 reviews available for ebselen and Brain Ischemia
| Article | Year |
|---|---|
[Cerebral ischaemia: tomorrow's therapeutic tracks].
Topics: Apoptosis; Astrocytes; Azoles; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Endothe | 2009 |
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica | 2005 |
Ebselen: prospective therapy for cerebral ischaemia.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Dogs; Humans; Isoindoles; Organoselenium Compounds; R | 2000 |
2 trials available for ebselen and Brain Ischemia
| Article | Year |
|---|---|
Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 1998 |
Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Antioxidants; Azoles; Brain Ischemia; Double-Blind Method; Female; Humans; Incidence; Intracra | 1998 |
17 other studies available for ebselen and Brain Ischemia
| Article | Year |
|---|---|
Design and biological evaluation of novel antioxidants containing N-t-Butyl-N-hydroxylaminophenyl moieties.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Cell Death; Cell Survival; Drug Design; Electron Spin | 2003 |
Ebselen alleviates white matter lesions and improves cognitive deficits by attenuating oxidative stress via Keap1/Nrf2 pathway in chronic cerebral hypoperfusion mice.
Topics: Animals; Brain Ischemia; Carotid Stenosis; Cognition; Cognitive Dysfunction; Demyelinating Diseases; | 2023 |
Effects of ebselen on ischemia/reperfusion injury in rat brain.
Topics: Animals; Azoles; Brain; Brain Ischemia; Catalase; Disease Models, Animal; Glutathione Peroxidase; Is | 2014 |
Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Brain Ischemia; Cell Survival; Cytokines; | 2014 |
Absence of glutathione peroxidase-1 exacerbates cerebral ischemia-reperfusion injury by reducing post-ischemic microvascular perfusion.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation; Disea | 2008 |
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes.
Topics: 4-Aminobutyrate Transaminase; Animals; Azoles; Blotting, Western; Brain Ischemia; Cell Death; Gerbil | 2009 |
Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide.
Topics: Animals; Azoles; Brain Ischemia; CA1 Region, Hippocampal; Cerebrovascular Circulation; Disease Model | 2011 |
Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia.
Topics: Animals; Antioxidants; Azoles; Brain Ischemia; Immunohistochemistry; Isoindoles; Male; Organoseleniu | 2003 |
Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.
Topics: Administration, Oral; Animals; Azoles; Body Weight; Brain; Brain Chemistry; Brain Ischemia; Drug Adm | 2004 |
Ebselen induced C6 glioma cell death in oxygen and glucose deprivation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Azoles; Brain Ischemia; Cell Death; | 2006 |
The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Topics: Animals; Antioxidants; Azoles; Blood Pressure; Brain Ischemia; Caudate Nucleus; Cerebral Cortex; Dis | 1995 |
Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Azoles; Brain Ischemia; Disease Mode | 1997 |
The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C.
Topics: Alkaloids; Alzheimer Disease; Animals; Antioxidants; Azoles; Benzophenanthridines; Brain Ischemia; C | 2000 |
Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia.
Topics: Animals; Antioxidants; Azoles; Brain; Brain Ischemia; Heme Oxygenase (Decyclizing); Heme Oxygenase-1 | 2000 |
Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia.
Topics: Animals; Antioxidants; Axons; Azoles; Brain; Brain Ischemia; Disease Models, Animal; DNA Damage; Inf | 2001 |
Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat.
Topics: Animals; Azoles; Behavior, Animal; Brain Ischemia; Drug Interactions; Grooming; Isoindoles; Lipid Pe | 2002 |
Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats.
Topics: Animals; Antioxidants; Azoles; Brain Edema; Brain Ischemia; Cats; Cerebrovascular Circulation; Isoin | 1990 |